المؤلفون: Patil, S, Tamirat, M, Khazhidinov, K, Ardizzoni, E, Atger, M, Austin, A, Baudin, E, Bekhit, M, Bektasov, S, Berikova, E, Bonnet, M, Caboclo, R, Chaudhry, M, Chavan, V, Cloez, S, Coit, J, Coutisson, S, Dakenova, Z, De Jong, B, Delifer, C, Demaisons, S, Do, J, Dos Santos Tozzi, D, Ducher, V, Ferlazzo, G, Gouillou, M, Khan, U, Kunda, M, Lachenal, N, LaHood, A, Lecca, L, Mazmanian, M, McIlleron, H, Moreau, M, Moschioni, M, Nahid, P, Osso, E, Oyewusi, L, Panda, S, Pâquet, A, Thuong Huu, P, Pichon, L, Rich, M, Rupasinghe, P, Salahuddin, N, Sanchez Garavito, E, Seung, K, Velásquez, G, Vallet, M, Varaine, F, Yuya-Septoh, F, Mitnick, C, Guglielmetti, L

المصدر: Trials. 24(1)

مصطلحات موضوعية: Bedaquiline, Clofazimine, Delamanid, Fluroquinolone-resistant, Linezolid, MDR-TB, Multidrug-resistant, Non-inferiority, Pre-XDR TB, RR-TB, Rifampicin-resistant, Stratified medicine, Treatment shortening, Tuberculosis, Humans, Extensively Drug-Resistant Tuberculosis, Fluoroquinolones, Clofazimine, Linezolid, Tuberculosis, Multidrug-Resistant, Antitubercular Agents, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/77z3m917
https://escholarship.org/content/qt77z3m917/qt77z3m917.pdf

المؤلفون: Patil, S, B, Tamirat, M., Khazhidinov, K., Ardizzoni, E., Atger, M., Austin, A., Baudin, E., Bekhit, M., Bektasov, S., Berikova, E., Bonnet, M., Caboclo, R., Chaudhry, M., Chavan, V., Cloez, S., Coit, J., Coutisson, S., Dakenova, Z., de Jong, B, C, Delifer, C., Demaisons, S., Do, J, M, dos Santos Tozzi, D., Ducher, V., Ferlazzo, G., Gouillou, M., Khan, U., Kunda, M., Lachenal, N., Lahood, A, N, Lecca, L., Mazmanian, M., Mcilleron, H., Moreau, M., Moschioni, M., Nahid, P., Osso, E., Oyewusi, L., Panda, S., Pâquet, A., Thuong Huu, P., Pichon, L., Rich, M, L, Rupasinghe, P., Salahuddin, N., Sanchez Garavito, E., Seung, K, J, Velásquez, G, E, Vallet, M., Varaine, F., Yuya-Septoh, F, J, Mitnick, C, D, Guglielmetti, L.

المساهمون: Epicentre Paris Médecins Sans Frontières, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)

المصدر: ISSN: 1745-6215 ; Trials ; https://hal.science/hal-04328211 ; Trials, 2023, 24 (1), pp.773. ⟨10.1186/s13063-023-07701-6⟩.

مصطلحات موضوعية: [SDV]Life Sciences [q-bio]

الاتاحة: https://hal.science/hal-04328211
https://hal.science/hal-04328211v1/document
https://hal.science/hal-04328211v1/file/Trials%202023_Guglielmetti.pdf
https://doi.org/10.1186/s13063-023-07701-6

المؤلفون: Patil, S. B., Tamirat, M., Khazhidinov, K., Ardizzoni, E., Atger, M., Austin, A., Baudin, E., Bekhit, M., Bektasov, S., Berikova, E., /Bonnet, Maryline, Caboclo, R., Chaudhry, M., Chavan, V., Cloez, S., Coit, J., Coutisson, S., Dakenova, Z., De Jong, B. C., Delifer, C., Demaisons, S., Do, J. M., Tozzi, D. D., Ducher, V., Ferlazzo, G., Gouillou, M., Khan, U., Kunda, M., Lachenal, N., LaHood, A. N., Lecca, L., Mazmanian, M., McIlleron, H., Moreau, M., Moschioni, M., Nahid, P., Osso, E., Oyewusi, L., Panda, S., Paquet, A., Huu, P. T., Pichon, L., Rich, M. L., Rupasinghe, P., Salahuddin, N., Garavito, E. S., Seung, K. J., Velásquez, G. E., Vallet, M., Varaine, F., Yuya-Septoh, F. J., Mitnick, C. D., Guglielmetti, L.

مصطلحات موضوعية: Fluroquinolone-resistant, Pre-XDR TB, Multidrug-resistant, Rifampicin-resistant, MDR-TB, RR-TB, Tuberculosis, Bedaquiline, Clofazimine, Delamanid, Linezolid, Treatment shortening, Non-inferiority, Stratified medicine

جغرافية الموضوع: Inde, Kazakhstan, Lesotho, Pakistan, Perou, Viet nam

Relation: https://www.documentation.ird.fr/hor/fdi:010088760; oai:ird.fr:fdi:010088760; Patil S. B., Tamirat M., Khazhidinov K., Ardizzoni E., Atger M., Austin A., Baudin E., Bekhit M., Bektasov S., Berikova E., Bonnet Maryline, Caboclo R., Chaudhry M., Chavan V., Cloez S., Coit J., Coutisson S., Dakenova Z., De Jong B. C., Delifer C., Demaisons S., Do J. M., Tozzi D. D., Ducher V., Ferlazzo G., Gouillou M., Khan U., Kunda M., Lachenal N., LaHood A. N., Lecca L., Mazmanian M., McIlleron H., Moreau M., Moschioni M., Nahid P., Osso E., Oyewusi L., Panda S., Paquet A., Huu P. T., Pichon L., Rich M. L., Rupasinghe P., Salahuddin N., Garavito E. S., Seung K. J., Velásquez G. E., Vallet M., Varaine F., Yuya-Septoh F. J., Mitnick C. D., Guglielmetti L. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q) : study protocol for a multi-country randomized controlled trial. 2023, 24 (1), p. 773 [14 p.]

الاتاحة: https://www.documentation.ird.fr/hor/fdi:010088760

المؤلفون: Guglielmetti, L.^1,2,3, Khan, U.^4,5, Vellsquez, G. E.^6,7, Gouillou, M., Abubakirov, A.^8,9, Baudin, E., Berikova, E.^8,9, Berry, C.³, Bonnet, M.¹⁰, Cellamare, M.¹¹, Chavan, V.¹², Cox, V.¹³, Dakenova, Z.¹⁴, de Jong, B. C.¹⁵, Ferlazzo, G.¹⁶, Karabayev, A.¹⁷, Kirakosyan, O.¹⁸, Kiria, N.¹⁹, Kunda, M.²⁰, Lachenal, N.¹⁶

المصدر: New England Journal of Medicine. 1/30/2025, Vol. 392 Issue 5, p468-482. 15p.

مصطلحات موضوعية: *THIRD grade (Education), *TUBERCULOSIS, *TUBERCULOSIS patients, *LINEZOLID, *CONFIDENCE intervals